|
|
||||||||
1 From the Departments of Ophthalmology and 2 Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland; and the 3 Department of Medicine, Wayne State University School of Medicine, Detroit, Michigan.
| Abstract |
|---|
|
|
|---|
METHODS. Inflammatory cells in the lacrimal glands of MRL/lpr and MRL/+ mice were evaluated for apoptosis with TUNEL staining and Fas and Fas ligand expression with immunohistochemistry.
RESULTS. MRL/lpr mice had a greater percentage of the lacrimal gland replaced by inflammatory infiltrate (30.3% ± 7.0%) than did MRL/+ mice (13.0% ± 3.0%, P = 0.02). However, similar amounts of lymphocytic apoptosis were present in the lacrimal glands of MRL/lpr and MRL/+ mice. The mean number of apoptotic cells per unit area of inflammation was 23.8 ± 2.4 in MRL/lpr mice and 24.6 ± 6.0 in MRL/+ mice (P = 0.91). Fas expression was absent on lymphocytes in MRL/lpr mice but was present on lymphocytes in MRL/+ mice. Fas ligand expression was present on epithelial structures in both substrains.
CONCLUSIONS. The accelerated lacrimal gland disease inflammation in MRL/lpr mice does not appear to be due to decreased apoptosis in the microenvironment of the lacrimal gland of MRL/lpr mice. It appears that in MRL/lpr mice there is defective extrathymic lymphoid apoptosis, permitting a relatively greater expansion of autoreactive T cells, which subsequently invade the lacrimal gland.
| Introduction |
|---|
|
|
|---|
| Materials and Methods |
|---|
|
|
|---|
TUNEL Staining
Slides were fixed in acetone for 5 seconds, washed once in
distilled water, and then dried at 42°C. Tissue sections were
immersed in 10 mM Tris-HCl at pH 8.0 for 5 minutes, incubated with 20
µg/ml proteinase K in 10 mM Tris-HCl for 15 minutes at room
temperature, and washed in double-distilled water (DDW) four times for
2 minutes each. To accomplish nuclear stripping, endogenous peroxidase
was inactivated by covering the sections with 100 to 200 µl 3%
hydrogen peroxide for 5 minutes at room temperature and rinsing in DDW.
Sections were preincubated in TdT buffer (1X: 30 mM tris base,
140 mM sodium cacodylate, pH 7.2, 1 mM cobalt chloride). Each slide was
incubated with 75 µl reaction mixture coverslips in a humid
atmosphere for 60 minutes at 37°C. The reaction mixture consisted of
TdT-buffered biotinylated-dUTP stock, and TdT at 0.3 enzyme units/µl,
final solution, in DDW. The reaction was terminated by transferring
slides to a bath of 300 mM NaC1 and 30 mM sodium citrate for 15 minutes
at room temperature. The slides were washed for 15 minutes at room
temperature with phosphate-buffered saline (PBS), blocked with 2%
bovine serum albumin for 10 minutes, and washed with PBS for 5 minutes.
The sections were incubated with avidin-conjugated peroxidase in PBS at
37°C for 30 minutes and stained with the 3-amino-9-ethylcarbazole
(AEC) reagent for 30 minutes at 37°C. Sections were then washed in
PBS. Light counterstaining with hematoxylin was performed, and slides
were mounted in glycerol-gelatin and covered.8
Because of
the loss of two sections from slides with proteolytic treatment, a
second series of experiments was performed omitting proteinase K
treatment. Before terminal transferase labeling the following steps
were used in this series. Slides were immersed in 1% hydrogen
peroxide/methanol for 30 minutes, washed twice with PBS,
blocked with the avidin-biotin blocking kit (Vector Laboratories,
Burlingame, CA) for 10 minutes, rinsed twice more with PBS, and labeled
with TdT buffer as above. No substantive differences were seen between
the two methods, and a total of nine slides for each strain was
available for analysis. The proportion of lymphocytes undergoing
apoptosis was counted with a net micrometer disc, which covered an area
of 0.35 mm2, and the number of cells staining
positively per unit area of inflammation was calculated. This area was
estimated to encompass an average of 59,600 cells. All foci of
inflammation in one histologic section of each lacrimal gland were
counted.
Immunohistochemistry
Lacrimal gland sections were fixed in chilled (4°C) acetone,
air-dried, rehydrated in PBS, and incubated with the appropriate
blocking agent (Vector Laboratories) for 20 minutes. Monoclonal
antibodies to Fas (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or
Fas ligand (Boehringer Mannheim, Indianapolis, IN)9
10
were applied, and the slides were incubated for 60 minutes. Slides were
washed in PBS and incubated with a biotinylated antibody for 30
minutes, rinsed in PBS, incubated with the ABC reagent for 45 minutes,
and washed again in PBS, and the reaction product was developed with
hydrogen peroxide in AEC containing acetate buffer and counterstained
with Harris hematoxylin or methyl green (Sigma, St. Louis,
MO).2
3
11
For each run and for each antibody, appropriate
positive controls (e.g., ocular, thymus, or spleen sections from
appropriate animals) and negative controls (tissues omitting the
primary antibody) were run to ensure quality control. A
semiquantitative scoring system was used for Fas staining as follows:
0, no staining; 1+, <25% cells positive; 2+, 25% to 50% cells
positive; 3+, 51% to 75% cells positive; and 4+, >75% cells
positive.
Lacrimal Gland Inflammation
The percentage of the lacrimal gland replaced by inflammation
was estimated with the net micrometer disc.
Statistics
Comparisons of the percentage of the lacrimal gland replaced by
inflammation and of the number of cells per unit area undergoing
apoptosis were performed with the two-sample t-test.
| Results |
|---|
|
|
|---|
|
|
|
|
| Discussion |
|---|
|
|
|---|
MRL/lpr mice have an accelerated course of autoimmune lacrimal gland inflammatory disease compared with MRL/+ mice. Specifically, the onset of diseases is earlier in MRL/lpr mice and the amount of inflammation is greater than in MRL/+ mice at comparable ages.3 Our data on the percentage of lacrimal gland occupied by the inflammatory infiltrate confirm these differences, because MRL/lpr mice had a significantly greater amount of disease. Because MRL/lpr and MRL/+ are congenic and differ only by the lpr gene, these experiments were performed to evaluate hypotheses as to how the defective Fas in MRL/lpr mice might accelerate the autoimmune lacrimal gland disease. Although it was possible that failure of apoptosis in the microenvironment of lacrimal gland in MRL/lpr mice permitted the inflammatory cells invading the lacrimal disease to accumulate at the site, our data do not provide support for this hypothesis. Instead, the amount of lymphocyte apoptosis was similar between MRL/lpr and MRL/+ mice. Apoptotic cells appeared to be haphazardly scattered throughout the inflammatory infiltrate, and no specific pattern could be discerned. MRL/+ mice appeared to have a greater variability in the number of apoptotic cells per unit area because of the low numbers of apoptotic cells present, the smaller size of the inflammatory infiltrates in MRL/+ mice, and the haphazard distribution of apoptotic cells, producing greater sampling variability in MRL/+ mice. However, because of the overall similarity in the amount of lymphocyte apoptosis in the lacrimal gland between the two substrains, the effect of the defective lymphocyte apoptosis in MRL/lpr mice appears to occur outside the lacrimal gland.
As anticipated, Fas staining was seen on the lymphocytes in the
lacrimal gland in MRL/+ mice but not in MRL/lpr mice, and Fas ligand
staining was present in both strains. Fas ligand expression on lacrimal
gland epithelial structures has been reported in other murine models of
Sjögrens syndrome.10
Although MRL/+ mice may use
the Fas ligand system to initiate lymphocyte apoptosis, MRL/lpr mice
cannot do so and must use alternative pathway(s) to initiate the
apoptosis seen in the lacrimal glands; these pathways could include the
tumor necrosis factor (TNF) receptor or death receptor 3, 4, or
5.14
Of note, MRL/lpr mice have been reported to have
elevated levels of TNF
.15
In the human disease
Sjögrens syndrome, Fas is expressed on the infiltrating
lymphocytes in the glands, and Fas ligand on the acinar epithelial
cells; however, apoptosis appears to be blocked, possibly by
bcl-2 expression.16
It is possible that, as in
human disease, lymphocytic apoptosis in the lacrimal gland is blocked
in both MRL/+ and MRL/lpr mice, resulting in reduced apoptosis in both
substrains; however, our data suggest that apoptosis is not blocked
differentially between the two substrains in the microenvironment of
the lacrimal gland.
Previous work has shown that MRL/lpr mice have defective lymphocyte apoptosis in peripheral (extrathymic) lymphoid organs.6 7 17 Our data demonstrate that the extent of apoptosis within the lacrimal gland inflammation is similar between MRL/lpr and MRL/+ mice. They also suggest that the accumulation of autoreactive lymphocytes, which is a consequence of the defective apoptosis in peripheral lymphoid organs, permits the expansion of that population of lymphocytes, which then invade the lacrimal gland in greater numbers in MRL/lpr than in MRL/+ mice and that this phenomenon is responsible for the accelerated lacrimal gland disease seen in MRL/lpr mice, when compared to its congenic substrain MRL/+.
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication May 19, 2000; revised September 7, 2000; accepted October 16, 2000.
Commercial relationships policy: N.
Corresponding author: Douglas A. Jabs, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, 550 North Broadway, Suite 700, Baltimore, MD 21205. djabs{at}jhmi.edu
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
D. S. Vinay, J. D. Kim, T. Asai, B. K. Choi, and B. S. Kwon Absence of 4 1BB Gene Function Exacerbates Lacrimal Gland Inflammation in Autoimmune-Prone MRL-Faslpr Mice Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4608 - 4615. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Barabino and M. R. Dana Animal Models of Dry Eye: A Critical Assessment of Opportunities and Limitations Invest. Ophthalmol. Vis. Sci., June 1, 2004; 45(6): 1641 - 1646. [Full Text] [PDF] |
||||
![]() |
E. K. Akpek, D. A. Jabs, H. C. Gerard, R. A. Prendergast, A. P. Hudson, B. Lee, and J. A. Whittum-Hudson Chemokines in Autoimmune Lacrimal Gland Disease in MRL/MpJ Mice Invest. Ophthalmol. Vis. Sci., January 1, 2004; 45(1): 185 - 190. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |